Be careful with biosimilars marketing, FDA and FTC say. We're watching

FDA Building 2
The FDA joined with the FTC to issue a statement about the two agencies' efforts in overseeing the biosimilars market. (FDA)

While the FDA already oversees biologic and biosimilar drug marketing, the agency, along with the Federal Trade Commission, recently reinforced a commitment to address misleading promotions and anti-competitive practices.

The two agencies released a joint statement detailing their promise to police promotional messaging as well as review patent agreements to prevent antitrust collations, share best practices and collaborate on public outreach. To the latter goal, they announced a public workshop on the “Competitive Marketplace for Biosimilars” on March 9 at FDA headquarters.

RELATED: Which asthma biologic do docs prefer? It's not that simple: analyst

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

“Given biosimilars are relatively new territory, FDA is making sure it puts up the markers of the lanes very clearly as more come to market. It achieves the policy goal of supporting the market by seeking to reinforce clarity in the market and uptake of less expensive meds,” Mark Senak, a lawyer and PR professional with expertise in regulatory communications and medical products, said in an email.

In the issued statement, the FDA also announced new draft guidance on which it will take submitted comments through April 2. The “Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products—Questions and Answers” filing is meant for manufacturers, packers, distributors and their reps to use when creating promotional labeling and ads for biosimilar products and reference materials.

The draft includes direction on how biosimilars makers should handle the use of reference names—the original biologic brand—in marketing materials. It notes that companies should be careful when using a reference product and a biosimilar product and should avoid suggesting that a biosimilar product is not highly similar to a reference product or that there are clinically meaningful differences.

For instance, a biosimilar drug could be touted as just as effective as its reference drug, but its maker couldn’t claim that it works better.

RELATED: Biologics and DTC: Mainstream ad campaigns now price of admission for biologic brands

While the rules for biosimilars are, well, similar to the rules the FDA uses to police all marketing, the newness of the emerging market and the difference between biosimilars and generic drugs (which are exact copies; biosimilars are not) likely inspired the proposal.

“I think the FDA/FTC announcement is meant to highlight that this is an area that is going to be looked at carefully and sends a signal that while such practices are already addressed, there is radar up that is examining promotional communications that may be in violation,” Senak said.

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.